Pharma Mar

Update in progress

PHM.MC (MCE)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

PharmaMar, S.A. is a Madrid-based biopharmaceutical company focused on oncology, combining research, development, production and commercialization of bioactive compounds, including RNA interference therapies, for markets in Europe, the United States and beyond. It markets Yondelis, Zepzelca and Aplidin, and is advancing candidates such as LAGOON, SaLuDo, PM534, PM54 and SYL1801 in various clinical phases. Founded 1986.

Company score

Sentiment: -0.29; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.18; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.18; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive